Open Access

Journal of Pharmacology and Therapeutics

Aiming To Make A New Nano-Formula To Regulate The Binding Of Recombinant Human Growth Hormone

Nader Namazi

Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, Taibah University, Al-Madinah, Al-Munawwarah, Saudi Arabia

Author's Information:
Nader Namazi
Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, Taibah University, Al-Madinah, Al-Munawwarah, Saudi Arabia

Received Date: Dec19, 2022
Accepted Date: Dec 31, 2022
Published Date: Jan 23, 2023

Abstract:

Because most biomolecules are unstable when they are being adsorbed on a hydrophobic polymer, the polymer surface can be altered to accommodate the way that proteins bind to it. Specific interaction domains that need substrate specificity are involved in the binding of a protein to a biomolecule. Protein-binding epitopes can be produced by isolating these interaction regions and integrating them into lengthy polypeptide chains. These exposed epitopes may be able to recognise their partners on the protein surface and attach firmly. Growth Hormone Binding Peptide (GHBpep), a brand-new r-hGH-binding peptide, covers the majority of the residues in the Growth Hormone Binding Protein (GHBP) hot spot, which is responsible for the majority of the binding energy with Recombinant Human Growth Hormone (r-hGH). Preparation and characterisation of peptide-modified Poly (Lactic-co-Glycolic) Acid are part of the study.

By covalently attaching GHBpep to the surface of these nanoparticles using traditional bioconjugation chemistry, peptide-modified Poly (Lactic-co-Glycolic) Acid (PLGA) nanoparticles are prepared and characterised for the study. Therefore, creating a polymer surface coated with peptides may provide a workable approach for the regulated administration of protein medicines. The study investigates how r-hGH adheres to these functionalized surfaces in further detail. Isothermal Titration Calorimetry was used to investigate the thermodynamics of GHBpep-r-hGH contacts whereas equilibrium microdialysis, fluorescence spectroscopy, and dynamic light scattering were used to investigate the adsorption with these surfaces under varied microenvironmental settings (ITC). Changes in the ionic strength, pH of the medium, and the length and reactivity of the cross-linker utilised were found to have an impact on the adsorption process.

The high affinity type of GHBpep-r-hGH's energetics were discovered to exist without significant configurational changes, suggesting the possibility of developing a dosage form of r-hGH with controlled release.

Keywords:
Human growth hormone; Growth hormone binding peptide; Poly (lactic-co-glycolic acid); Nanoparticles; Emulsification; Adsorption

Introduction:

The majority of proteins may bind to hydrophobic or hydrophilic surfaces, which is advantageous when creating formulations for sustained release. To provide a targeted delivery location with few adverse effects, a wide range of medicines, including vaccines and biological macromolecules, can be integrated into or adsorbed onto the nanoparticles [1-3]. Furthermore, numerous studies have demonstrated that proteins' irreversible adsorption onto hydrophobic polymer surfaces results in the loss of the protein's structural integrity and, as a result, its biological activity [4]. However, by functionalizing a polymer with ligands that have particular binding capabilities to these proteins, the surface properties of a polymer can be modified to limit the nonspecific adsorption. A viable method for delivering protein therapeutics is designing a polymer-based system, especially for a labile protein like recombinant Human Growth Hormone (r-hGH).

The primary application of r-hGH is as a replacement therapy for the treatment of paediatric dwarfism. Patient compliance will be impacted by the treatment's requirement for numerous subcutaneous injections over an extended period of time.

In order to increase the half-life of this protein medication, biodegradable polymer is used to encapsulate it in microspheres. A long-acting, refined version of r-hGH called Nutropin Depot is combined with micronized PLAG particles. The unregulated release of r-hGH and the typical injection-site reaction were the preparation's drawbacks [5]. The surface of the polymer may become damaged and lose stability when a protein interacts with it. The r-hGH structure may be safeguarded and non-specific adsorption prevented by applying a peptide coating to the surface of the polymeric microspheres [6]. It has 191 residues in a single chain, starting at which about half of the polypeptides
are in the form of α-helical structure [7].

When proteins are present in non-physiological environments, their three-

dimensional structures can change, which complicates our understanding of the adsorption process (Figure 1) [8]. The protein structure is significantly altered when r-hGH adsorbs on a polymer's hydrophobic surface [9,10]. Modulating the polymer surface with tiny biomolecules, such as peptides, can reduce protein structural deformation. Additionally, it has been demonstrated that the surface coating of polymer nanoparticles limits irreversible adsorption and regulates the non-specific interaction of proteins [11,12].

A recent area of research is the use of peptide coatings to alter the way that therapeutic proteins bind to surfaces. A potential inert carrier for therapeutic proteins is peptide-coated nanoparticles [13,14]. Using databases with peptide-protein compounds as a base, it Small peptides have been discovered to interact with their target proteins with high binding energy and little protein conformational changes [14].

So, utilising a specialised ligand termed Growth Hormone Binding Peptide (GHBpep), which interacts with r-hGH with high binding affinity, we want to functionalize the surface of polymeric nanoparticles. We expected that r-hGH adsorption to peptide-coated hydrophobic surfaces will allow high loading levels of r-hGH and will lessen denaturation of r-hGH based on the ITC data we acquired from the interaction between r-hGH and GHBpep. In order to maximise the specific binding of r-hGH, our effort entailed manufacturing and altering the surface of PLGA nanoparticles with GHBpep molecules.

A stabiliser, such as Poly-Ethylene Maleic Anhydride (PEMA) or Polyethyleneimine (PEI), was embedded to create PLGA nanoparticles with a high concentration of functional groups [11, 15]. The study continued with the synthesis and characterisation of peptide-modified PLGA nanoparticles by covalently attaching GHBpep on the surface of the nanoparticles using a variety of crosslinkers after the augmentation of the functional groups on the nanoparticles' surface was accomplished. The effectiveness of two monovalent linkers in enhancing ligand conjugation was evaluated. The amount of r-hGH was enhanced by increasing the ligand binding sites. The spacers' length and chemical reactivity had an impact on how well the conjugates adhered to r-hGH. The purpose of the present study was to investigate and quantify the r-adsorption hGH's behaviour to a peptide-coated colloidal system.

Materials and Methods:

Purchased from Alkermes (Medisorb®, Wilmington, OH) was PLGA copolymer with a molecular weight of 48 kDa, lactide: glycolide ratio of 85:15 (PLGA 85:15), and intrinsic viscosity of 0.59 dL/g. We bought r-hGH from BresaGen, Inc. (Adelaide, Australia.) PEMA, with an average molecular weight of 100,000–500,000 g/mol, was acquired from Sigma-Aldrich (St. Louis, MO) and hydrolyzed before to use. Sigma-Aldrich was also used to purchase polyethyleneimine (PEI), which is 50% by weight and has a high molecular weight (W=720,000 g/mol, Wn=60,000). AAPPTEC created GHBpep (M=3296 g/mol), Figure 2. (Louisville, KY). We bought N-Hydroxy Succinimide (NHS) and 1-Ethyl-3- (3-dimethylaminopropyl) Carbodiimide (EDC) from Sigma-Aldrich Co. LLC. Thermo Scientific Pierce Protein Biology Products supplied the Disuccinimidyl Suberate (DSS) for this project (Rockford, IL).We bought cellulose ester (CE) dialysis membranes from SpectraPor.

The analytical-grade chemicals dichloromethane, 2-(N-morpholino) ethanesulfonic acid (MES), sodium chloride, sodium azide, and sodium hydroxide solution were acquired from Sigma-Aldrich (St. Louis, MO). All dialysis membranes from Spectrum® Laboratories (Rancho Cucamonga) were of various Molecular Weight Cut-Offs (MWCO).CA Dominguez). Sigma-Aldrich provided an ultra filtration tube (Corning®, Spin-XR UF 500) with a 100 kDa MCOW. PEMA and buffer solutions were created using reverse osmosis-purified nanopure water (Barnstead Ultra filtered type I water), which was also used to wash microspheres.

A modified method described in the literature [11,16], emulsification solventdiffusion methods, was used to create PLGA nanoparticles. In order to create nanoparticles with a smaller particle size (300 nm) and a higher density of functional groups, several distinct techniques were used in this process. The aqueous phase was represented by 10 mL of 4% PEMA solution (or 1% PEI in the case of positive PLGA np) that was transferred to a 20 mL glass vial and placed on a magnetic stirrer at a speed of 1000 Rounds per Minute (rpm). Then, to create a single emulsion (W/O), 1 mL of PLGA solution (1% w/v) in organic solvent was applied drop by gentle drop to the surface of the aqueous phase.

Cold nano-pure water was used during the experiment to avoid raising the solvent temperature, which could cause the organic phase to evaporate during the emulsification process. The emulsion was immediately added to 50 mL of diluted emulsifier solution (0.03% of PEMA or PEI) following the mixing step and stirred magnetically for three hours to harden the nanoparticles and allow the entire organic solvent to evaporate. Using a large-volume centrifuge, the produced PLGA nanoparticles were separated using the centrifugation process (Beckman centrifuge, Model J2-21).

Discussion:

Nanoparticle Creation and Characterization: There are several ways to make PLGA nanoparticles [27], but the most popular one is emulsification solvent-diffusion. The single oil in water emulsion (O/W) was created, and the nanodroplets were created by dropping small amounts of the organic phase into the aqueous phase while vigorously stirring (at a speed of about 1000 rpm). The organic phase was slowly added into the aqueous phase while being constantly stirred at a very high speed, which greatly reduced the size of the nano-droplets. Due to the spontaneous diffusion of the organic phase, the employment of a mixture of suitable organic solvents results in interfacial turbulence between the solvent molecules [16]. One of these organic solvents, ethanol, which is 95% water-miscible by volume, enables fast diffusion from the combination.

Surfactant concentration's impact on a nanoparticle's properties: a favourable yield of nanoparticles depending on the polymer even at low PLGA concentrations, concentration was attained. This was unquestionably caused by the solution's high viscosity, which improved PLGA's ability to disperse in the aqueous phase [28]. When PEMA is used as a surfactant, the organic droplets are stabilised and coated with additional carboxyl acid groups, creating strong repulsive forces between the nanoparticles. However, the zeta potential and ultimate PEMA concentration in the emulsion at the time of nanoparticle formation may differ. According to Kwon et al. [29], the smaller the particle size, the more stabilisers were employed.Because the interfacial tension between the emulsion phases is decreasing as a result of this process, the particle size is reduced [12].

The mean particle size decreased to 76 nm at 2% applied concentration of the cationic Didodecyl dimethyl Ammonium Bromide (DMAB) surfactant. A modest reduction in particle size was noticed with a greater DMAB molecule concentration (4%). Surface tension is significantly reduced by DMAB surfactant [29]. Therefore, using a larger surfactant concentration will result in smaller nanoparticles and an increase in zeta potential. However, even a small amount of surfactant reduces the density of functional groups and creates an unstable system of nanoparticles. After being lyophilized, the nanoparticles showed a greater mean particle size upon reconstituting, as determined by the Zetasizer ZS. The particles in the aqueous dispersion may have swollen, which could be the cause [12].

GHBpep-PLGA nanoparticle conjugation:

Using DSS linker to crosslink GHBpep peptides to PLGA nanoparticles: By using PEI as a stabiliser, PLGA nanoparticles containing amino groups on the surface were created. There was an additional step in the coupling reactions employing the DSS monovalent linker. The lysine (K) residue in position 11 of the GHBpep molecule can be used as an anchor for the DSS reagent. The DSS linkers and GHBpep molecules were concurrently added to the nanoparticle suspensions in each aliquot, keeping the total volume of the solution at 1 ml. Because they exclusively attack the amino groups, the NHS ester groups only react with the principal amino groups on molecules such as PLGA nanoparticles and GHBpep molecules [30]. The biomolecules and linker had a molar ratio of optimized by using an overabundance of DSS molecules. The ideal ratio (1:400) to reduce the increase of mean particle size was 10 mM DSS concentration. The zeta potential of the intermediate and final conjugation reaction products was also impacted by the varying molar ratio. The surface became unstable as a result of the NHS moieties of DSS reducing the charge density on particles.

The observed number of bound ligands was high in comparison to the low ratio of the linker to GHBpep when using a high concentration of DSS linker. The density of activated groups and attached GHBpep molecules on the surface were indicated by the zeta potential values of the intermediate product and final conjugates as well as the change in particle charges.

Conclusion:

Using two different kinds of linkers, EDC and DDS, GHBpep ligands could be conjugated to nanoparticles with customised surfaces. Overall, the amount of r-hGH adsorbed and the structural stability of the conjugates based on EDC linkers were favourable under pH 7.2 and 5.3. These conjugates may prove to be a crucial step in the development of sustained r-hGH delivery if desorption experiments are carried out on them at physiological pH. To improve the loading efficiency of biomolecules like GHBpep and r-hGH, different linkers may be used.

References

1. Danhier F, Ansorena E, Silva JM, Coco R, Breton AL, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release.2012;161(2):505-22.

2. Witzigmann D, Wu D, Schenk SH, Balasubramanian V, Meier W, Huwyler J.Biocompatible Polymer–Peptide Hybrid-Based DNA Nanoparticles for Gene Delivery. ACS Appl Mater Interfaces. 2015;7(19):10446-56.

3. Vendruscolo M, Dobson CM. Chemical biology: More charges against aggregation.Nature. 2007;449(7162):555.

4. Wertz CF, Santore MM. Effect of surface hydrophobicity on adsorption and relaxation kinetics of albumin and fibrinogen: single-species and competitive behavior.Langmuir. 2001;17(10):3006-16.

5. Johnson OL, Cleland JL, Lee HJ, Charnis M, Duenas E, Jaworowicz W, et al. A month– long effect from a single injection of microencapsulated human growth hormone. NatMed. 1996;2(7):795-9.

6. Fine RN, Kohaut EC, JD DB, Perlman AJ. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. J Pediatr. 1994;124(3):374-82.

7. Wicar S, Mulkerrin MG, Bathory G, Khundkar LH, Karger BL, et al. Conformational changes in the reversed phase liquid chromatography of recombinant human growth hormone as a function of organic solvent: the molten globule state. Anal Chem. 1994;66(22):3908-15.

8. Oroszlan P, Wicar S, Teshima G, Wu SL, Hancock WS, Karger BL. Conformational effects in the reversed-phase chromatographic behavior of recombinant human growth hormone (rhGH) and N-methionyl recombinant human growth hormone (Met-hGH). Anal Chem. 1992;64(14):1623-31.

9. De Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and

extracellular domain of its receptor: crystal structure of the complex. Science. 1992;255(5042):306-12.

10. Park MR, Chun C, Ahn SW, Ki MH, Cho CS, Song SC. Sustained delivery of human growth hormone using a polyelectrolyte complex-loaded thermosensitive polyphosphazene hydrogel. J Control Release. 2010;147(3):359-67.

11. Keegan ME, Falcone JL, Leung TC, Saltzman WM.Biodegradable microspheres with enhanced capacity for covalently bound surface ligands. Macromolecules.2004;37:9779-84.

12. Manoocheheri S, Darvishi B, Kamalinia G, Amini M, Fallah M, Ostad SN, et al.Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel. DARU J Pharmaceut Sci. 2013;21(1):58.

13. Klok HA. Peptide/protein-synthetic polymer conjugates: Quo vadis. Macromolecules.2009;42(21):7990-8000.

14. London N, Movshovitz-Attias D, Schueler-Furman O. The structural basis of peptideprotein binding strategies. Structure. 2010;18(2):188-99.

15. Zhou J, Moya S, Ma L, Gao C, Shen J. Polyelectrolyte coated PLGA nanoparticles:templation and release behavior. Macromol Biosci. 2009;9(4):326-35.

16. Chang J, Paillard A, Passirani C, Morille M, Benoit JP, Betbeder D, et al. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res. 2012;29(6):1495-505.

17. Zhu S, Panne U, Rurack K. A rapid method for the assessment of the surface group density of carboxylic acid-functionalized polystyrene microparticles. Analyst.2013;138(10):2924-30

18. Montesano L, Cawley D, Herschman HR. Disuccinimidyl suberate cross-linked ricin does not inhibit cell-free protein synthesis. Biochem Biophys Res Commun.1982;109(1):7-13.

19. Fischer MJ. Amine coupling through EDC/NHS: a practical approach. Methods Mol Biol. 2010;627:55-73.

20. Sartor M. Dynamic light scattering. University of California, San Diego. 2003:2-21.

21. Schuhmacher J, Kohlsdorfer C, Bühner K, Brandenburger T, Kruk R. High-throughput determination of the free fraction of drugs stronglybound to plasma proteins. J Pharm Sci. 2004;93(4):816-30.

22. Kariv I, Cao H, Oldenburg KR. Development of a high throughput equilibrium dialysis method. J Pharm Sci. 2001;90(5):580-7.

23. Buijs J, Britt DW, Hlady V. Human growth hormone adsorption kinetics and conformation on self-assembled monolayers. Langmuir. 1998;14(2):335-41.

24. Clark SR, Billsten P, Mandenius CF, Elwing H. Fluorimetric investigation of recombinant human growth hormone adsorbed on silica nanoparticles. Analytica chimica acta. 1994;290(1-2):21-6.

25. Adams PD, Chen Y, Ma K, Zagorski MG, Sönnichsen FD, McLaughlin ML, et al.Intramolecular quenching of tryptophan fluorescence by the peptide bond in cyclic hexapeptides. J Am Chem Soc. 2002;124(31):9278-86.

26. Shah VR, Gupta pk. Structural Stability of Recombinant Human Growth Hormone(r-hGH) as a Function of Polymer Surface Properties. Pharm Res. 2018;35(5):98.

27. 27. Shah S, Patel VR, Thakkar AY, Vaghani ZH, Shah S, Shah SH. Nanotechnology: a review on revolution in cancer treatment. Pharm Rev. 2008;6(6).

28. Murakami H, Kobayashi M, TakeuchibYoshi H, washim K. Preparation of poly (DLlactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int j pharm. 1999;187(2):143-52.

29. Kwon HY, Lee JY, Choi SW, Jang Y, Kim JH. Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method. Colloids Surf A Physicochem Eng Asp. 2001;182(1-3):123-30.

30. Partis MD, Griffiths DG, Roberts GC, Beechey RB. Cross-linking of protein by ω-maleimido alkanoylN-hydroxysuccinimido esters. J Protein Chem. 1983;2:263-77.

31. Gubala V, Guevel XL, Nooney R, Williams DE, MacCraith B. A comparison of mono and multivalent linkers and their effect on the colloidal stability of nanoparticle and immunoassays performance. Talanta. 2010;81(4):1833-9.

32. Ross PD, Subramanian S. Thermodynamics of protein association reactions: forces contributing to stability. Biochemistry. 1981;20(11):3096-102.

33. Seelig J, Ganz P. Nonclassical hydrophobic effect in membrane binding equilibria.Biochemistry. 1991;30(38):9354-9.

34. Kondo A, Oku S, Higashitani K. Structural changes in protein molecules adsorbed on ultrafine silica particles. J Colloid Interface

Sci. 1991;143(1):214-21.

35. Ghisaidoobe A, Chung S. Intrinsic tryptophan fluorescence in the detection and analysis of proteins: a focus on Förster resonance energy transfer techniques. Int J Mol Sci. 2014;15(12):22518-38.

36. Chantalat L, Jones ND, Korber F, Navaza J, Pavlovsky AG. The crystalstructure of wild-type growth hormone at 2.5 Aresolution. Protein Pept Lett. 1995;2:333-340.